F3 and neoplasm: Given its aberrant expression in other solid tumors and its known internalizing capacity (48), an antibody–drug conjugate targeting CD142 has also been studied to induce tumor regression in patient-derived xenograft models of solid tumors (49) and a recent multicenter phase I–II trial demonstrated its manageable safety profile in patients with solid tumor (NCT02001623; ref. 50).